<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01200420</url>
  </required_header>
  <id_info>
    <org_study_id>SPC3649-203</org_study_id>
    <secondary_id>2010-019057-17</secondary_id>
    <nct_id>NCT01200420</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects</brief_title>
  <official_title>A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Antiviral Activity of SPC3649 (Miravirsen) Administered to Treatment-Naïve Subjects With Chronic Hepatitis C (CHC) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santaris Pharma A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santaris Pharma A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine the safety and tolerability of multiple dosing
      of miravirsen in subjects infected with chronic hepatitis C.

      Secondary purpose includes assessment of pharmacokinetics of miravirsen and assessment of
      miravirsen's effect on HCV viral titer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>regularly over 18 weeks</time_frame>
    <description>Safety evaluation will study the adverse event (AE) profile, clinical laboratory safety tests, vital signs, 12 lead and ECG monitoring.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>continuously over 4 weeks</time_frame>
    <description>Appropriate PK parameters, e.g. maximum observed plasma drug concentrations, area under the plasma concentration-time curves, the apparent terminal rate constant and corresponding half-life for miravirsen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miravirsen treatment effect on viral titer</measure>
    <time_frame>regularly over 18 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>miravirsen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation study with review of safety data following each cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose escalation study with review of safety data following each cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>miravirsen</intervention_name>
    <description>SC injection</description>
    <arm_group_label>miravirsen</arm_group_label>
    <other_name>SPC3649</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>SC injection</description>
    <arm_group_label>saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 18-38 kg/m2

          -  Treatment-naïve to interferon-alpha based therapies

          -  HCV genotype 1

          -  Clinical and laboratory findings consistent with a clinical diagnosis of CHC,
             including:

        Previous documentation of positive HCV serology (HCV antibody or HCV RNA) at least 24 weeks
        prior to enrollment, OR Positive HCV serology (HCV antibody or HCV RNA) with a prior remote
        risk factor (more than 24 weeks prior to Screening) for the acquisition of hepatitis C

          -  Serum HCV RNA &gt; 75,000 IU/mL at Screening

          -  (North American sites only). Liver biopsy within 36 months of Day 1, indicating the
             absence of cirrhosis

          -  Screening hematology, clinical chemistries, coagulation and urinalysis are not
             clinically significant and the following criteria are met:

          -  Platelets &gt;100,000/mm3

          -  Total WBC &gt; 3000/mm3 and ANC &gt;1500/mm3

          -  Hemoglobin &gt; 11 g/dL for females and &gt; 12 g/dL for males

          -  Total and direct bilirubin, WNL (except for clearly documented Gilbert's Syndrome)

          -  ALT &lt; 5 x ULN

          -  Serum creatinine WNL and creatinine clearance as calculated by the Cockcroft-Gault
             formula &gt; 80 ml/min

          -  Negative results on the following Screening laboratory tests: urine or serum pregnancy
             test (for women of childbearing potential), hepatitis B surface antigen and human
             immunodeficiency virus (HIV) antibody.

          -  For men and women of childbearing potential, willingness to utilize adequate
             contraception and not become pregnant (or have their partner become pregnant) during
             the full course of the study. Adequate contraceptive measures include oral
             contraceptives (stable use for 2 or more cycles prior to Screening). IUD,
             Depo-Provera, Norplant System implants, bilateral tubal ligation, vasectomy, condom or
             diaphragm plus either contraceptive sponge, foam or jelly and abstinence.

        Exclusion Criteria:

          -  Other known cause of liver disease except for CHC

          -  History or symptoms of decompensated liver disease: Child-Pugh Class B or C, including
             ascites, hepatic encephalopathy, esophageal variceal bleeding, fibrosis or other signs
             of hepatic insufficiency or portal hypertension

          -  History of hepatocellular carcinoma (HCC) on imaging studies or serum
             alpha-fetoprotein (AFP) &gt; 50 ng/mL at Screening

          -  Concurrent clinically significant medical diagnosis (other than hepatitis C-related
             conditions) that would potentially interfere with the subjects study compliance or
             confound study results

          -  Concurrent social conditions (e.g. drugs, alcohol, transportation) which would
             potentially interfere with the subject's study compliance

          -  Clinically significant illness within 30 days preceding entry into the study

          -  Participated in an investigational drug study within 30 days or 5 half-lives,
             whichever is longer, prior to the start of study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Zeuzem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>J.W. Goethe University Hospital, Frankfurt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alamo Medical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J.W. Goethe University Hospital</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center (AMC)</name>
      <address>
        <city>Amsterdam</city>
        <zip>22660 1100 D</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC University Hospital</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Hepatologii i Nabytych Niedoborow Immunologicznych WUM</name>
      <address>
        <city>Warszawa</city>
        <zip>01-201</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion de Investigation de Diego</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FNsP Bratislava, Nemocnica akad.</name>
      <address>
        <city>Bratislava,</city>
        <zip>833 05</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Slovakia</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Romania</country>
  </removed_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2010</study_first_submitted>
  <study_first_submitted_qc>September 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2010</study_first_posted>
  <last_update_submitted>January 26, 2012</last_update_submitted>
  <last_update_submitted_qc>January 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antisense</keyword>
  <keyword>miR-122 antagonist</keyword>
  <keyword>host factor</keyword>
  <keyword>CHC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

